FDA 510(k) Clearances: Ranking Top Medical Imaging AI Developers

Lots of medical imaging AI companies talk a big game about their regulatory wins, but when you actually dig into the FDA’s 510(k) clearances, you find a much smaller group of real players than most VCs realize. While marketing departments are busy touting breakthroughs, the real proof of who’s leading and developing products quickly is buried in the regulatory approval data. This is a look at that hard data, cutting through the noise to rank developers by their FDA 510(k) clearance volume and the clinical evidence they have to back it up.

The FDA 510(k) as a Bellwether for Product Development Velocity

For any VC focused on medical imaging and diagnostics, an FDA 510(k) clearance is way more than a regulatory check-box. It’s a direct signal of a company’s ability to get an actual product to market. This pathway, which requires showing substantial equivalence to an existing device, is the fastest route for most cardiac and other medical AI software. A company’s speed in getting these clearances says everything about its operational maturity and engineering discipline. It shows they can handle the bureaucracy. Just think about the implications of the FDA guidance on PCCPs for AI/ML medical devices (Predetermined Change Control Plan). If you don’t have one of these plans for your adaptive AI, every single time your team retrains a model on new data, you could be facing a whole new 510(k) submission. That creates a regulatory debt that can absolutely cripple innovation. So, the number of clearances, and how fast a company gets them, shows a strong product pipeline and a regulatory team that knows what it’s doing.

Comparative Ranking: Clearance Volume and Clinical Validation Density

When you pull the records from the FDA 510(k) public database and clean them up, a clear pecking order emerges. A lot of companies have one or two clearances. A select few are consistently pushing algorithms through the process, building a real portfolio. The raw count of clearances matters less than the strategic deployment of those AI solutions across diverse clinical indications. Take Aidoc. They have 31 FDA 510(k) clearances as of May 2026, which shows an incredibly broad strategy across different radiological findings and modalities. That kind of regulatory footprint points to a very mature development process and a smart plan for getting into different parts of the hospital. Their repeat success in the 510(k) process shows they have strong tech and a deep understanding of the clinical workflows that the FDA needs to see. Similarly, Zebra Medical Vision had a big portfolio before being acquired by Nanox AI in August 2021, and Nanox.AI has kept up the pace, hitting 10 FDA clearances for its own AI tools by April 2022. This isn’t an accident. It’s a commitment. Beyond the simple count, the depth of clinical validation is what really matters. You can check the ACR Data Science Institute registry to see which cleared algorithms are actually being used and validated in real clinics. While the 510(k) is about equivalence, strong peer-reviewed clinical studies are the evidence you need to get paid by insurers and to get doctors to actually adopt the tech. Companies that consistently publish outcomes data for their cleared products are demonstrating a commitment to efficacy, making it a much safer bet for VCs.

Translating Clearance Data into Investment Insight

For a VC, this FDA clearance data is a predictive tool for a company’s future.

Here’s how to use this data in your due diligence:

• Product Development Velocity: A high number of clearances in a short time frame means the R&D cycle is efficient and they have a clear product roadmap. This company can likely iterate fast and bring new things to market without getting stuck.
• Regulatory Acumen: A long list of clearances means they have deep expertise in working with the FDA’s requirements. This is a huge deal, it removes a massive amount of future regulatory risk from the investment.
• Market Expansion Potential: Each clearance often opens up a new clinical use case or indication. A wide portfolio of clearances means a bigger addressable market and more shots on goal for generating revenue.
• Clinical Validation Commitment: Look for strong, peer-reviewed clinical studies supporting the cleared algorithms, even though it’s not a strict 510(k) requirement. This signals genuine clinical utility and a proactive plan for building the Real-World Evidence (RWE) needed to secure reimbursement and drive adoption.

When you’re looking at an AI-native company, for example, you can see this in their regulatory velocity. They often build the regulatory strategy into product development from day one, which makes the whole clearance process much cleaner than for a company that just bought an AI tool as a “bolt-on” acquisition.

Methodology and Source Note

Our ranking comes from pulling and cleaning records from the FDA 510(k) public database. To get our numbers, we focused on medical imaging AI devices, counted the clearances for each developer, checked the timelines, and cross-referenced everything with public information on peer-reviewed clinical studies for those algorithms. Of course, any prospective investor should do their own deep dive into the specifics of each clearance and the clinical data behind it. The ACR Data Science Institute registry is another great place to look to understand how these tools are actually being deployed. The data is clear: while a lot of companies want to lead the radiology AI market, only a few have shown they can consistently execute on the regulatory front and back it up with clinical evidence. For VCs, understanding this quantitative reality is the key to making smart investments in this space.